Deutsche Bank initiates its coverage on Neurocrine NBIX with a Buy rating and a price target of $15 as it believes share valuation is underestimated.
Deutsche Bank notes, "We rate NBIX shares BUY because currently shares reflect only value to Elagolix in endometriosis & zero to pipeline. We believe upside this year will be driven by increased investor confidence in VMAT2 and Elagolix in uterine fibroids."
NBIX closed at $8.50 a share on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetInitiationPre-Market OutlookAnalyst RatingsBiotechnologyDeutsche BankHealth Care
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in